Discovering Novel Retinal Vascular Models to Translate Neovascularization Targets Beyond Anti-VEGF into the Clinic
March 19 - 21, 2024 | Boston, MA
Accelerating Novel Retinal Vascular Target R&D into the Clinic
The 4ᵗʰ Wet AMD & Diabetic Eye Disease Drug Development Summit is returning to Boston this March to unite 70+ industry-based retinal vascular experts from the likes of Bayer, Boehringer Ingelheim, Genentech, Novartis and OcuTerra, at the only industry-dedicated forum to transform the potential of treatment of chronic, sight-threatening retinal vascular diseases to improve patient outcomes.
Join the most comprehensive Wet AMD & Diabetic Eye Disease forum to:
- Hear data-driven case studies from industry experts from the likes of Bayer, Boehringer Ingelheim, Novartis and Genentech
- Participate with the interactive expert panel discussion navigating the current anti-VEGF treatment
- Meet and network with industry-based retinal vascular preclinical and clinical R&D scientists from Annexin Pharmaceuticals, OcuTerra Therapeutics, University of Southern California, Kodiak Sciences and more
Don’t miss out on hearing from 18+ expert speakers working on the discovery of new targets and modalities, preclinical models to replicate the retinal vasculature, and accelerating their retinal drugs into the clinic.
18+ World-Class Pharma & Biotech Expert Speakers Include:
Past Companies in Attendance Included:
Proud to Partner With:
Industry News:
“Great content from the most relevant players and very nice speakers from clinician and industry sides. Worth the time”
Senior Leader, Clinical Program, Ophthalmology, Clinical Development & Medical Affairs, Boehringer Ingelheim
Other Events in the Ophthalmology & Sensory Series:
Download the Full Event Guide for More Information On:
- Expert Speaker Faculty
- Full Access to the 3-day Conference Agenda
- Audience Breakdown
- & more